RET-IN-19

Modify Date: 2025-08-22 00:21:11

RET-IN-19 Structure
RET-IN-19 structure
Common Name RET-IN-19
CAS Number 2484919-71-1 Molecular Weight 544.62
Density N/A Boiling Point N/A
Molecular Formula C28H28N6O4S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of RET-IN-19


RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].

 Names

Name RET-IN-19

 RET-IN-19 Biological Activity

Description RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research[1].
Related Catalog
Target

EGFR:56.78 ± 4. μM (IC50)

Aurora A:0.242 ± 0. μM (IC50)

Aurora B:0.536 ± 45 μM (IC50)

MAP4K4:3.428 ± 0. μM (IC50)

In Vitro RET-IN-19 (compound 59) shows growth inhibition of LC-2/ad cells which RET-CCDC6 driven, with a GI50 of 0.1067 ± 0.004 μM[1]. RET-IN-19 (3 μM) shows inhibition of LC-2/ad cells migration[1]. RET-IN-19 inhibits EGFR, Aurora A, Aurora B, Nek2, CSF-1R, MAP4K4, NIK, and RET, with IC50 values of 56.78 ± 4.94, 0.242 ± 0.036, 0.536 ± 45.12, >200, 1.65 ± 0.235, 3.428 ± 0.150, >10, and 0.0068 ± 0.0003, respectively[1].
References

[1]. Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691.

 Chemical & Physical Properties

Molecular Formula C28H28N6O4S
Molecular Weight 544.62
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.